FABENTECH
Budget
€50 — €0
EP Access
0
accredited persons
Staff
3
0.45 FTE
EU Grants
€963,751
Mission & Goals
Founded in 2009, Fabentech specialises in the development and production of broad-spectrum therapeutics for fighting high-priority biological agents which could threaten public health. Our platform is based on a safe, tested and fully validated polyclonal antibody technology, initially developed by Sanofi Pasteur and enhanced by the Fabentech R&D team for more than a decade. Our Integrated R&D and proprietary manufacturing site enable rapid developments of medical countermeasures against different targets. We are using our expertise to offer reliable protection and treatments ready to face proliferating risks. Fabentech’s mission is to collaborate closely with governments and healthcare organisations, providing timely and effective medical countermeasures to combat highly pathogenic agents during public health crises. We help nations to build robust preparedness plans that enable effective anticipation and response to potential future pandemics and bioterror attacks.
EU Legislative Interests
The Covid-19 crisis revealed the low preparedness of nations to face emerging diseases and major public health issues. In a context of increased risk of pandemics and bioterrorist attacks, treatments are lacking, and no relevant therapeutic option can fight the acute symptoms from these new biothreats. As a biotech company developing and producing treatments in Europe against biothreats. FABENTECH aims to participate to the construction of EU preparedness plans to prevent future pandemics and responses regarding health security. As a consequence we are interested in policies and decisions including: - Pandemic preparedness plans and stockpiling strategies organized through DG HERA - Union Civil Protection Mechanism (rescEU) - Fundings from European Defence Fund to fund research to develop medical countermeasures against Chemical, Biological, Radiological and Nuclear risks - Council decisions, EU parliament resolutions and Commission decisions regarding CBRN Action Plan - Cross-Border Health Threats Regulation - Strategy and decisions regarding the EU FAB mechanism to support EU sovereignty of the supply chain regarding medical countermeasures and health products. - European Health Union - EU Recovery and Resilience Funds - European Pharmaceutical Strategy - EU4Health - Market access strategies from the European Medical Agency regarding emergency treatments in case of outbreaks.
Communication Activities
FABENTECH takes part in meetings organized for the Joint Industrial Cooperation Forum by DG HERA. FABENTECH announced through a press release and a dedicated event in September 2024 that it has received €20 million in EIB financing under the HERA Invest programme to strengthen preparedness against biological threats. Representatives from DG HERA and the EIB participated in a media conference in Lyon, France, to mark the occasion. in February 2025, FABENTECH also organized a roundtable discussion, Boosting European Biological Preparedness: CBRN and Biotoxin Threats, with the support of the French Chamber of Commerce in Brussels. The event brought together key stakeholders, including representatives from DG HERA and DG ECHO, for discussions on enhancing Europe’s resilience to emerging biological threats. This was a closed-door discussion under Chatam House rule.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
The company has memberships to the following associations: - LyonBiopole, the regional cluster in biotechnology - https://lyonbiopole.com/en/ - Mab Design, the french cluster in immunotherapy - https://www.mabdesign.fr/en/
Organisation Members
NA
Additional Information
As a biotech company we only receive EU grants for résearch and development activities.
Commissioner Meetings
No recorded meetings with EU commissioners.